EMA should remain in London post-Brexit to soften transition, UK lawmakers hear

The British pharmaceutical industry’s leading trade group told a UK government committee this morning that it would favor “a pragmatic agreement” where parts of the European Medicines Agency would stay in London after Brexit.

The House of Commons committee has been tasked with examining the potential impact on the pharmaceutical sector of the UK’s departure from the European Union, which is due to occur in March 2019.

As UK and EU negotiators prepare to discuss the terms of a future trading relationship, Mike Thompson, the head of the Association of the British Pharmaceutical Industry (ABPI) gave evidence calling for continued integration of medicines regulations.